Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Educational and organizational interventions to improve the usefulness of clinical pharmacological advice for personalized drug dosing based on therapeutic drug monitoring.

Pea F, Dose L, Cojutti P, Baraldo M, Fontana F, Favaretti C, Furlanut M.

Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):432-7. doi: 10.1111/bcpt.12249. Epub 2014 May 3.

2.
3.

Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients.

Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M.

J Antimicrob Chemother. 2012 Aug;67(8):2034-42. doi: 10.1093/jac/dks153. Epub 2012 May 2.

PMID:
22553142
4.

Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy.

Pea F, Cojutti P, Pagotto A, Cristini F, Furlanut M, Viale P.

Antimicrob Agents Chemother. 2012 Jun;56(6):3438-40. doi: 10.1128/AAC.00135-12. Epub 2012 Feb 27.

5.

Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Pea F, Cojutti P, Petrosillo N, Furlanut M, Entenza JM, Veloso TR, Vouillamoz J, Giddey M, Moreillon P.

Antimicrob Agents Chemother. 2011 Sep;55(9):4496; author reply 4496-7. doi: 10.1128/AAC.00603-11. No abstract available.

6.

TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient.

Pea F, Cojutti P, Sbrojavacca R, Cadeo B, Cristini F, Bulfoni A, Furlanut M.

Ann Pharmacother. 2011 Jul;45(7-8):e37. doi: 10.1345/aph.1P745. Epub 2011 Jul 12.

PMID:
21750307
7.

Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α.

Furlanut M, Soardo G, Donnini D, Sechi L, Franceschi L.

Clin Pharmacokinet. 2010 Nov;49(11):767-72. doi: 10.2165/11534720-000000000-00000.

PMID:
20923249
8.

Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.

Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P.

Antimicrob Agents Chemother. 2010 Nov;54(11):4605-10. doi: 10.1128/AAC.00177-10. Epub 2010 Aug 23.

9.

Is the use of vancomycin doses of at least 1 g every 8 hours the only way to achieve optimal trough levels in critically ill trauma patients with pneumonia and normal renal function?

Pea F, Furlanut M, Viale P.

J Trauma. 2010 Mar;68(3):748-9. doi: 10.1097/TA.0b013e3181c9912e. No abstract available.

PMID:
20220431
10.

Validation of limited sampling strategy for estimation of mycophenolic acid exposure during the first year after heart transplantation.

Baraldo M, Cojutti PG, Isola M, Feruglio MT, Tursi V, Livi U, Furlanut M.

Transplant Proc. 2009 Dec;41(10):4277-84. doi: 10.1016/j.transproceed.2009.08.077.

PMID:
20005384
11.

What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?

Pea F, Furlanut M, Viale P.

Antimicrob Agents Chemother. 2009 Aug;53(8):3608-9; author reply 609-10. doi: 10.1128/AAC.00256-09. No abstract available.

12.
13.

Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients.

Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, Viale P.

Antimicrob Agents Chemother. 2009 May;53(5):1863-7. doi: 10.1128/AAC.01149-08. Epub 2009 Feb 17.

14.

A simple method to monitor serum concentrations of fluoxetine and its major metabolite for pharmacokinetic studies.

Franceschi L, Faggiani A, Furlanut M.

J Pharm Biomed Anal. 2009 Feb 20;49(2):554-7. doi: 10.1016/j.jpba.2008.11.017. Epub 2008 Nov 27.

PMID:
19117710
15.

Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin.

Viale P, Furlanut M, Scudeller L, Pavan F, Negri C, Crapis M, Zamparini E, Zuiani C, Cristini F, Pea F.

Int J Antimicrob Agents. 2009 Apr;33(4):379-82. doi: 10.1016/j.ijantimicag.2008.09.011. Epub 2008 Dec 18.

PMID:
19097864
16.

Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients.

Pea F, Viale P, Lugano M, Baccarani U, Pavan F, Tavio M, Adani GL, Della Rocca G, Furlanut M.

J Antimicrob Chemother. 2009 Jan;63(1):167-9. doi: 10.1093/jac/dkn442. Epub 2008 Oct 24.

PMID:
18952619
17.

Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.

Pea F, Baccarani U, Tavio M, Cojutti P, Adani GL, Londero A, Baraldo M, Franceschi L, Furlanut M, Viale P.

Ann Pharmacother. 2008 Nov;42(11):1711-6. doi: 10.1345/aph.1L330. Epub 2008 Sep 23.

PMID:
18812562
18.

Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.

Pea F, Tavio M, Pavan F, Londero A, Bresadola V, Adani GL, Furlanut M, Viale P.

Antivir Ther. 2008;13(5):739-42.

PMID:
18771060
19.

Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients.

Pea F, Pavan F, Furlanut M.

Clin Pharmacokinet. 2008;47(7):449-62. Review.

PMID:
18563954
20.

Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Pea F, Viale P, Pavan F, Furlanut M.

Clin Pharmacokinet. 2007;46(12):997-1038. Review.

PMID:
18027987
21.

Daunorubicin and daunorubicinol tissue concentrations in gastric cancer patients after local administration of a liposomal preparation.

Furlanut M, de Manzoni G, Pasini F, Tasselli S, Tomezzoli A, Poz D, Franceschi L.

Pharmacol Res. 2007 Oct;56(4):344-9. Epub 2007 Aug 24.

PMID:
17904378
22.

Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women.

Furlanut M, Franceschi L, Pasqual E, Bacchetti S, Poz D, Giorda G, Cagol P.

Ther Drug Monit. 2007 Jun;29(3):349-52.

PMID:
17529893
23.

Major role of levofloxacin in the treatment of a case of Listeria monocytogenes meningitis.

Viale P, Furlanut M, Cristini F, Cadeo B, Pavan F, Pea F.

Diagn Microbiol Infect Dis. 2007 May;58(1):137-9. Epub 2007 Mar 26.

PMID:
17368798
24.

Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose.

Pea F, Marioni G, Pavan F, Staffieri C, Bottin R, Staffieri A, Furlanut M.

Pharmacol Res. 2007 Jan;55(1):38-41. Epub 2006 Oct 10.

PMID:
17092740
25.

Chronopharmacokinetics of ciclosporin and tacrolimus.

Baraldo M, Furlanut M.

Clin Pharmacokinet. 2006;45(8):775-88. Review.

PMID:
16884317
26.

Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective.

Pea F, Poz D, Viale P, Pavan F, Furlanut M.

J Antimicrob Chemother. 2006 Aug;58(2):380-6. Epub 2006 May 30.

PMID:
16735422
27.

Acute oxcarbazepine, benazepril, and hydrochlorothiazide overdose with alcohol.

Furlanut M, Franceschi L, Poz D, Silvestri L, Pecorari M.

Ther Drug Monit. 2006 Apr;28(2):267-8.

PMID:
16628142
28.

The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin.

Pea F, Viale P, Pavan F, Tavio M, Poz D, Beltrame A, Furlanut M.

Int J Antimicrob Agents. 2006 Apr;27(4):344-50. Epub 2006 Mar 22.

PMID:
16554146
29.

Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis.

Pea F, Pavan F, Lugatti E, Dolcet F, Talmassons G, Screm MC, Furlanut M.

Clin Pharmacokinet. 2006;45(3):287-95.

PMID:
16509760
30.

Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient.

Pea F, Scudeller L, Lugano M, Baccarani U, Pavan F, Tavio M, Furlanut M, Rocca GD, Bresadola F, Viale P.

Clin Infect Dis. 2006 Feb 1;42(3):434-5. No abstract available.

PMID:
16392096
31.

Pharmacokinetic-pharmacodynamic aspects of antimicrobial prophylaxis with teicoplanin in patients undergoing major vascular surgery.

Pea F, Furlanut M, Stellini R, Bonardelli S, Signorini L, Pavan F, Matheis A, Portolani N, Lorenzotti S, Giulini SM, Viale P, Carosi G.

Int J Antimicrob Agents. 2006 Jan;27(1):15-9. Epub 2005 Dec 15.

PMID:
16343858
33.

Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.

Pea F, Viale P, Damiani D, Pavan F, Cristini F, Fanin R, Furlanut M.

Antimicrob Agents Chemother. 2005 Aug;49(8):3550-3.

34.

Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients.

Baraldo M, Isola M, Feruglio MT, Francesconi A, Franceschi L, Tursi V, Livi U, Furlanut M.

Transplant Proc. 2005 Jun;37(5):2240-3.

PMID:
15964387
35.

Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery.

Pea F, Ferrari E, Pavan F, Roman-Pognuz D, Bandello F, Furlanut M.

Antimicrob Agents Chemother. 2005 Jun;49(6):2554-7.

37.

Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases.

Pea F, Viale P, Lugano M, Pavan F, Scudeller L, Della Rocca G, Furlanut M.

Am J Kidney Dis. 2004 Dec;44(6):1097-102.

PMID:
15558532
38.

Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients.

Pea F, Furlanut M.

J Chemother. 2004 Apr;16 Suppl 2:8-10. Review. No abstract available.

PMID:
15255555
39.

Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.

Pea F, Viale P, Candoni A, Pavan F, Pagani L, Damiani D, Casini M, Furlanut M.

Clin Pharmacokinet. 2004;43(6):405-15.

PMID:
15086277
40.
41.

Pharmacology of ifosfamide.

Furlanut M, Franceschi L.

Oncology. 2003;65 Suppl 2:2-6. Review.

PMID:
14586139
42.

Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy.

Pea F, Pavan F, Nascimben E, Benetton C, Scotton PG, Vaglia A, Furlanut M.

Antimicrob Agents Chemother. 2003 Oct;47(10):3104-8.

43.

Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.

Pea F, Russo D, Michieli M, Damiani D, Fanin R, Michelutti A, Michelutti T, Piccolrovazzi S, Baccarani M, Furlanut M.

Clin Pharmacokinet. 2003;42(9):851-62.

PMID:
12882589
44.

Circadian variations in cyclosporine C2 concentrations during the first 2 weeks after liver transplantation.

Baraldo M, Risaliti A, Bresadola F, Chiarandini P, Dalla Rocca G, Furlanut M.

Transplant Proc. 2003 Jun;35(4):1449-51.

PMID:
12826188
45.

Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.

Pea F, Di Qual E, Cusenza A, Brollo L, Baldassarre M, Furlanut M.

Clin Pharmacokinet. 2003;42(6):589-98.

PMID:
12793843
46.

MEGX disposition in critically-ill trauma patients: subsequent assessments during the first week following trauma.

Pea F, Licari M, Baldassarre M, Furlanut M.

Fundam Clin Pharmacol. 2002 Dec;16(6):519-25.

PMID:
12685511
47.

Antimicrobial agents in elective surgery: prophylaxis or "early therapy"?

Pea F, Viale P, Furlanut MI.

J Chemother. 2003 Feb;15(1):3-11. Review.

PMID:
12678408
48.

Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose.

Pea F, Brollo L, Viale P, Pavan F, Furlanut M.

J Antimicrob Chemother. 2003 Apr;51(4):971-5. Epub 2003 Feb 25.

PMID:
12654757
49.

Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections.

Furlanut M, Brollo L, Lugatti E, Di Qual E, Dolcet F, Talmassons G, Pea F.

J Antimicrob Chemother. 2003 Jan;51(1):101-6.

PMID:
12493793
50.

C(2) monitoring of cyclosporine in stable heart transplant patients after two daily and three daily doses.

Baraldo M, Francesconi A, Barbone F, Tursi V, Livi U, Furlanut M.

Transplant Proc. 2002 Dec;34(8):3246-8. No abstract available.

PMID:
12493435

Supplemental Content

Loading ...
Support Center